Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Rocketing Higher Today

By George Budwell - Apr 17, 2020 at 7:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna's COVID-19 vaccine candidate lands a major award from the U.S. Federal government.

What happened

Shares of the mid-cap biopharma Moderna, Inc. (MRNA 4.97%) spiked by as much as 17% in pre-market action Friday morning. The biotech's shares are surging this morning in response to a $483 million award from the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.

This government-based financing will be used to accelerate the development of Moderna's messenger RNA (mRNA) vaccine candidate, mRNA-1273, against the novel coronavirus. This experimental SARS-CoV-2 vaccine is presently in an early-stage trial, which is being conducted by the National Institutes of Health.  

A doctor holding a vial that reads "COVID-19 Vaccine."

Image source: Getty Images.

So what

This rather large award should cover mRNA-1273's entire developmental costs all the way through to licensure by the Food and Drug Administration. That's a big deal because clinical-stage companies like Moderna tend to have enormous cash burn rates, forcing them to repeatedly dilute shareholders through large secondary offerings. 

Now what

When will this vaccine be available for widespread public consumption? Moderna is hopeful that mRNA-1273 can enter into a late-stage trial by this fall. So, in short, this mRNA vaccine might hit the market by mid to late 2021 under a best-case scenario. 

Is Moderna's stock worth buying on this news? Vaccine development is an extremely risky proposition. A lot can go wrong between now and the vaccine's regulatory review. As such, this clinical-stage biotech stock probably shouldn't be in your portfolio unless you have an above-average tolerance for both risk and volatility. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.